A
Accera
Biotechnology company engaged in the discovery and development of therapeutic drugs for neurodegenerative diseases
About Accera
Accera Pharma, accessible via accerapharma.com, is a dynamic startup focused on developing innovative solutions for brain health. The company operates in the pharmaceutical and biotechnology market, targeting a global audience that includes patients, healthcare providers, and research institutions. Accera Pharma specializes in creating treatments for neurological conditions, aiming to improve the quality of life for individuals suffering from brain-related health issues.
Read full description
The business model of Accera Pharma revolves around extensive research and development (R&D) to create proprietary drugs and therapies. The company invests heavily in clinical trials and regulatory approvals to ensure the safety and efficacy of its products. By doing so, Accera Pharma aims to bring groundbreaking treatments to market, addressing unmet medical needs in the field of neurology.
Accera Pharma generates revenue through the commercialization of its developed drugs. This includes direct sales to healthcare providers and partnerships with larger pharmaceutical companies for distribution. Additionally, the company may engage in licensing agreements, allowing other firms to market its products in exchange for royalties. This diversified approach helps Accera Pharma to maximize its market reach and financial stability.
The company serves a wide range of clients, including patients with neurological conditions, healthcare professionals seeking advanced treatment options, and research institutions interested in collaborative projects. By focusing on brain health, Accera Pharma positions itself in a niche yet critical segment of the healthcare industry, where there is a growing demand for innovative solutions.
In summary, Accera Pharma is a forward-thinking biotech startup dedicated to advancing brain health through innovative drug development. The company operates in the pharmaceutical and biotechnology market, serving patients, healthcare providers, and research institutions. Its business model is centered on R&D, clinical trials, and strategic partnerships, generating revenue through product sales and licensing agreements.
At a glance
- Status
- Operational
- Founded
- 2001
- Headquarters
- Denver, United States
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 36.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Accounting, Developer Tools, Biotechnology, Oncology, DNA, Surgery, Neurology, Genetics and genomics, Alzheimers Disease
- Business model
- Manufacturing
- Investment activity
- 1 company, latest Aug 2017
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Oct 2018 | $50M | $200M | Wilmar International | — |
| EARLY VCOther financing | Mar 2018 | $18M | $70M | Undisclosed | — |
Growth signals
Latest recorded traffic for Accera is 0 monthly website visits. Accera's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- PBPOSCO BioVentures
POSCO Venture Capital
INventages Venture Capital
Series B and later1 investor entered at this stage
Wilmar International
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Accera on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Accera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.